LU91624I2 - Canakinumab et ses dérivés pharmaceutiquement acceptables (ILARIS®) - Google Patents

Canakinumab et ses dérivés pharmaceutiquement acceptables (ILARIS®)

Info

Publication number
LU91624I2
LU91624I2 LU91624C LU91624C LU91624I2 LU 91624 I2 LU91624 I2 LU 91624I2 LU 91624 C LU91624 C LU 91624C LU 91624 C LU91624 C LU 91624C LU 91624 I2 LU91624 I2 LU 91624I2
Authority
LU
Luxembourg
Prior art keywords
ilaris
canakinumab
pharmaceutically acceptable
acceptable derivatives
derivatives
Prior art date
Application number
LU91624C
Other languages
English (en)
Other versions
LU91624I9 (fr
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9898090&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU91624(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of LU91624I2 publication Critical patent/LU91624I2/fr
Publication of LU91624I9 publication Critical patent/LU91624I9/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
LU91624C 2000-08-22 2009-11-25 Canakinumab et ses dérivés pharmaceutiquement acceptables (ILARIS®) LU91624I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0020685.4A GB0020685D0 (en) 2000-08-22 2000-08-22 Organic compounds
PCT/EP2001/009588 WO2002016436A2 (fr) 2000-08-22 2001-08-20 ANTICORPS DE LA IL-1β HUMAINE

Publications (2)

Publication Number Publication Date
LU91624I2 true LU91624I2 (fr) 2010-01-25
LU91624I9 LU91624I9 (fr) 2018-11-19

Family

ID=9898090

Family Applications (1)

Application Number Title Priority Date Filing Date
LU91624C LU91624I2 (fr) 2000-08-22 2009-11-25 Canakinumab et ses dérivés pharmaceutiquement acceptables (ILARIS®)

Country Status (37)

Country Link
US (3) US7446175B2 (fr)
EP (1) EP1313769B2 (fr)
JP (2) JP4271936B2 (fr)
KR (2) KR100910789B1 (fr)
CN (1) CN100547003C (fr)
AR (1) AR035581A1 (fr)
AT (1) ATE396206T1 (fr)
AU (2) AU9549001A (fr)
BE (1) BE2009C057I2 (fr)
BR (1) BR0113420A (fr)
CA (1) CA2420231C (fr)
CY (2) CY1108779T1 (fr)
CZ (1) CZ304470B6 (fr)
DE (2) DE60134148D1 (fr)
DK (1) DK1313769T4 (fr)
EC (1) ECSP034490A (fr)
ES (1) ES2305110T5 (fr)
FR (1) FR09C0062I2 (fr)
GB (1) GB0020685D0 (fr)
HK (1) HK1061403A1 (fr)
HU (2) HU228159B1 (fr)
IL (2) IL154465A0 (fr)
LU (1) LU91624I2 (fr)
MX (1) MXPA03001590A (fr)
MY (1) MY130248A (fr)
NL (1) NL300427I1 (fr)
NO (3) NO332609B1 (fr)
NZ (2) NZ524199A (fr)
PE (1) PE20020319A1 (fr)
PL (1) PL212480B1 (fr)
PT (1) PT1313769E (fr)
RU (1) RU2286351C2 (fr)
SI (1) SI1313769T2 (fr)
SK (1) SK288089B6 (fr)
TW (1) TWI321568B (fr)
WO (1) WO2002016436A2 (fr)
ZA (1) ZA200301275B (fr)

Families Citing this family (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2426710A1 (fr) * 2000-11-08 2002-10-10 Human Genome Sciences, Inc. Anticorps a liaison immunospecifique avec les recepteurs "trail"
NZ605429A (en) * 2002-09-06 2014-08-29 Amgen Inc Therapeutic human anti-il-1r1 monoclonal antibody
US7101978B2 (en) * 2003-01-08 2006-09-05 Applied Molecular Evolution TNF-α binding molecules
EP1590369B1 (fr) * 2003-01-24 2016-03-16 Applied Molecular Evolution, Inc. Antagonistes de l'il-1 beta humaine
GB0303337D0 (en) 2003-02-13 2003-03-19 Celltech R&D Ltd Biological products
WO2004100987A2 (fr) * 2003-05-06 2004-11-25 Regeneron Pharmaceuticals, Inc. Procede d'utilisation d'antagonistes de l'il1 pour le traitement d'hyperplasie neointimale
NZ549040A (en) 2004-02-17 2009-07-31 Schering Corp Use for interleukin-33 (IL33) and the IL-33 receptor complex
JP4989456B2 (ja) * 2004-02-26 2012-08-01 ベイラー リサーチ インスティテュート 関節炎の全身処置のための組成物および方法
EP1851245B1 (fr) * 2005-01-26 2012-10-10 Amgen Fremont Inc. Anticorps dirigés contre l'interleukine-1 beta
AU2012213934B9 (en) * 2005-01-26 2013-07-25 Amgen Fremont Inc. Antibodies against interleukin-1 beta
GB0509512D0 (en) * 2005-05-10 2005-06-15 Novartis Ag Organic compounds
PL2163562T3 (pl) * 2005-06-21 2014-03-31 Xoma Us Llc Przeciwciała wiążące IL-1 beta i ich fragmenty
JP2009511545A (ja) * 2005-10-14 2009-03-19 ノボ・ノルデイスク・エー／エス Ｉｌ−１インヒビターを使用する糖尿病の治療
EP3332807B1 (fr) * 2005-10-26 2023-02-22 Novartis AG Utilisation d' anticorps anti il-1beta
KR20080109093A (ko) * 2006-04-14 2008-12-16 노파르티스 아게 안과 장애 치료를 위한 ｉｌ－1 항체의 용도
CN103405768A (zh) * 2006-12-20 2013-11-27 爱克索马技术有限公司 用于治疗IL-1β相关疾病的方法
CL2008001071A1 (es) * 2007-04-17 2009-05-22 Smithkline Beecham Corp Metodo para obtener anticuerpo penta-especifico contra il-8/cxcl8, gro-alfa/cxcl1, gro-beta/cxcl2), gro-gama/cxcl3 y ena-78/cxcl5 humanas; anticuerpo penta-especifico; proceso de produccion del mismo; vector, hbridoma o celela que lo comprende; composicion farmceutica; uso para tratar copd, otras enfermedades.
EP1997832A1 (fr) * 2007-05-29 2008-12-03 Ganymed Pharmaceuticals AG Anticorps monoclonaux contre la claudine-18 pour le traitement contre le cancer
CA3080328C (fr) * 2007-05-29 2022-06-21 Novartis Ag Nouvelles indications pour une therapie anti-il-1-beta
US8637029B2 (en) 2007-12-20 2014-01-28 Xoma Technology Ltd. Methods for the treatment of gout
CN102076355B (zh) 2008-04-29 2014-05-07 Abbvie公司 双重可变结构域免疫球蛋白及其用途
US9109026B2 (en) 2008-06-03 2015-08-18 Abbvie, Inc. Dual variable domain immunoglobulins and uses thereof
EP3002299A1 (fr) 2008-06-03 2016-04-06 AbbVie Inc. Immunoglobulines à deux domaines variables et leurs utilisations
EP2293816B1 (fr) * 2008-06-06 2012-11-07 XOMA Technology Ltd. Procédés pour le traitement de la polyarthrite rhumatoïde
KR20110031369A (ko) 2008-07-08 2011-03-25 아보트 러보러터리즈 프로스타글란딘 ｅ2 이원 가변 도메인 면역글로불린 및 이의 용도
EP2341936A4 (fr) * 2008-09-05 2012-07-25 Xoma Technology Ltd PROCÉDÉS POUR LE TRAITEMENT OU LA PRÉVENTION DES MALADIES ASSOCIÉES À IL-1ß
NZ592094A (en) * 2008-10-20 2013-01-25 Abbott Lab Antibodies that bind to il-18 and methods of purifying the same
US8298533B2 (en) * 2008-11-07 2012-10-30 Medimmune Limited Antibodies to IL-1R1
EP2196476A1 (fr) 2008-12-10 2010-06-16 Novartis Ag Formulation d'anticorps
US20130122008A1 (en) * 2009-05-06 2013-05-16 Novartis Ag Anti-IL 1- ß Antibody Combination Therapy
US8389474B1 (en) * 2009-07-14 2013-03-05 Alan Anson Wanderer Rationale for IL-1 β targeted therapy to improve harvested organ viability, allograft tolerance, replant success and for conditions characterized by reduced or absent arterial perfusion
NZ598929A (en) * 2009-09-01 2014-05-30 Abbvie Inc Dual variable domain immunoglobulins and uses thereof
CN102666875A (zh) * 2009-10-15 2012-09-12 雅培制药有限公司 双重可变结构域免疫球蛋白及其用途
ES2622366T3 (es) 2009-10-26 2017-07-06 F. Hoffmann-La Roche Ag Procedimiento para la producción de una inmunoglobulina glucosilada
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
SG2014014724A (en) * 2010-05-07 2014-07-30 Xoma Technology Ltd METHODS FOR THE TREATMENT OF IL-1ß RELATED CONDITIONS
BR112013002578A2 (pt) 2010-08-03 2019-05-14 Abbvie Inc. imunoglobinas de domínio variável duplo e usos das mesmas
AU2011293253B2 (en) 2010-08-26 2014-12-11 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
AU2012242666A1 (en) 2011-04-15 2013-11-28 Merck Patent Gmbh Anti- IL-1R1 inhibitors for use in cancer
WO2013007763A1 (fr) 2011-07-12 2013-01-17 Universität Zürich Modulateurs de la voie d'il-1β de l'inflammasome nlrp3 destiné à la prévention ou au traitement de l'acné
DE102011083595A1 (de) 2011-09-28 2013-03-28 Bayer Pharma AG Inhibition der Wirkung von Interleukin 1 beta zur Behandlung der Endometriose
BR112014007253A2 (pt) * 2011-09-30 2017-03-28 Novartis Ag uso de anticorpos que se ligam a il-1beta
AP2014007680A0 (en) 2011-12-02 2014-06-30 Novartis Ag Anti-1L-beta (interleukin-1beta) antibody-based prophylactic therapy to prevent complications leading to vaso-occlusion in sickle cell disease
US10118958B2 (en) * 2011-12-14 2018-11-06 AbbVie Deutschland GmbH & Co. KG Composition and method for the diagnosis and treatment of iron-related disorders
US9573996B2 (en) 2011-12-16 2017-02-21 Synthon Biopharmaceuticals B.V. Monoclonal antibodies to human proinflammatory cytokines and methods for treating inflammatory diseases
CN104144946A (zh) 2011-12-19 2014-11-12 爱克索马美国有限责任公司 治疗痤疮的方法
TW201333035A (zh) 2011-12-30 2013-08-16 Abbvie Inc 針對ｉｌ－１３及／或ｉｌ－１７之雙特異性結合蛋白
RS60583B1 (sr) 2012-02-13 2020-08-31 Agency Science Tech & Res Ljudska monoklonalna antitela koja vrše neutralizaciju il-ss
CN103588878A (zh) * 2012-08-15 2014-02-19 江苏泰康生物医药有限公司 一种人源化抗人白细胞介素1 β单克隆抗体及其制备与应用
MY194330A (en) 2012-11-01 2022-11-28 Abbvie Inc Anti-dll4/vegf dual variable domain immunoglobulin and uses thereof
KR102345999B1 (ko) * 2012-11-05 2021-12-30 델레넥스 쎄라퓨틱스 아게 Il-1 베타 결합성분
EP2919811B1 (fr) 2012-11-16 2018-12-26 Novartis AG Utilisation d'anticorps de liaison à il-1-bêta pour le traitement de la maladie artérielle périphérique
EP2931750B8 (fr) 2012-12-17 2021-11-03 Cell Medica Inc. Anticorps dirigés contre il-1 béta
TW201427989A (zh) 2012-12-18 2014-07-16 Novartis Ag 長效性蛋白質之組合物及方法
CN105324396A (zh) 2013-03-15 2016-02-10 艾伯维公司 针对IL-1β和/或IL-17的双重特异性结合蛋白
WO2015083120A1 (fr) 2013-12-04 2015-06-11 Novartis Ag Utilisation d'anticorps de liaison à il-1β
WO2015198243A2 (fr) 2014-06-25 2015-12-30 Novartis Ag Compositions et procédés pour protéines à action longue
WO2015198240A2 (fr) 2014-06-25 2015-12-30 Novartis Ag Compositions et procédés permettant d'obtenir des protéines à action prolongée
WO2016008851A1 (fr) * 2014-07-14 2016-01-21 Boehringer Ingelheim International Gmbh Anticorps anti-il-1b
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
CN114920840A (zh) 2014-10-14 2022-08-19 诺华股份有限公司 针对pd-l1的抗体分子及其用途
CA2963606A1 (fr) 2014-11-10 2016-05-19 F.Hoffmann-La Roche Ag Anticorps anti-ang2 et methodes d'utilisation correspondantes
CN107074941A (zh) 2014-11-10 2017-08-18 豪夫迈·罗氏有限公司 双特异性抗体和用于眼科学的方法
US10093733B2 (en) 2014-12-11 2018-10-09 Abbvie Inc. LRP-8 binding dual variable domain immunoglobulin proteins
CA2988055A1 (fr) 2015-06-04 2016-12-08 Novartis Ag Utilisation d'anticorps de liaison il-1 beta pour traiter une maladie arterielle peripherique
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
EP3964528A1 (fr) 2015-07-29 2022-03-09 Novartis AG Polythérapies comprenant des molécules d'anticorps dirigées contre lag-3
EP3878465A1 (fr) 2015-07-29 2021-09-15 Novartis AG Polythérapies comprenant des molécules d'anticorps tim-3
AU2016369537B2 (en) 2015-12-17 2024-03-14 Novartis Ag Antibody molecules to PD-1 and uses thereof
EP3426775A1 (fr) 2016-03-10 2019-01-16 Novartis AG Arn messager chimiquement modifié
WO2018015897A1 (fr) 2016-07-21 2018-01-25 Novartis Ag Utilisation de l'anticorps canakinumab se liant à l'il-1 beta pour le traitement ou le soulagement des symptômes de la sarcoïdose pulmonaire.
EP4252629A3 (fr) 2016-12-07 2023-12-27 Biora Therapeutics, Inc. Procédés, dispositifs et systèmes de détection du tractus gastro-intestinal
CA3046093A1 (fr) 2016-12-14 2018-06-21 Progenity Inc. Traitement d'une maladie du tractus gastro-intestinal avec un inhibiteur d'il-1
UY37758A (es) 2017-06-12 2019-01-31 Novartis Ag Método de fabricación de anticuerpos biespecíficos, anticuerpos biespecíficos y uso terapéutico de dichos anticuerpos
WO2018235056A1 (fr) 2017-06-22 2018-12-27 Novartis Ag Anticorps se liant à il-1beta destinés à être utilisés dans le traitement du cancer
JP2020524694A (ja) 2017-06-22 2020-08-20 ノバルティス アーゲー がんの処置における使用のためのＩＬ−１β結合性抗体
TW201919695A (zh) 2017-08-25 2019-06-01 瑞士商諾華公司 康納單抗(canakinumab)之用途
JP2020533353A (ja) 2017-09-13 2020-11-19 ノバルティス アーゲー アルコール性肝炎の治療のためのｉｌ−１ｂ結合抗体の使用
AU2018368731A1 (en) 2017-11-16 2020-05-14 Novartis Ag Combination therapies
JP2021523894A (ja) * 2018-05-09 2021-09-09 ノバルティス アーゲー カナキヌマブの使用
BR112020024351A2 (pt) 2018-06-01 2021-02-23 Novartis Ag moléculas de ligação contra bcma e usos das mesmas
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
GB2575853A (en) * 2018-07-25 2020-01-29 Robert Wotherspoon Hugh IL-1ß binding antibody
CN110818793A (zh) * 2018-08-14 2020-02-21 中山康方生物医药有限公司 抗IL-1β的抗体、其药物组合物及其用途
WO2020039401A1 (fr) 2018-08-24 2020-02-27 Novartis Ag Traitement comprenant des anticorps se liant à il-1 βeta et ses combinaisons
JP7256266B2 (ja) * 2018-11-07 2023-04-11 沢達生物医薬有限公司 ヒトＩＬ－１βに結合する抗体、その調製方法及び用途
EP3883634A1 (fr) 2018-11-19 2021-09-29 Progenity, Inc. Méthodes et dispositifs pour traiter une maladie à l'aide d'agents biothérapeutiques
AU2019402189B2 (en) 2018-12-20 2023-04-13 Novartis Ag Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
EP3897613A1 (fr) 2018-12-21 2021-10-27 Novartis AG Utilisation d'anticorps de liaison à il-1bêta
GB201901187D0 (en) 2019-01-29 2019-03-20 Autolus Ltd Treatment of neurotoxicity and/or cytokine release syndrome
BR112021015783A2 (pt) 2019-02-15 2021-10-05 Novartis Ag Derivados de 3-(1-oxo-5-(piperidin-4-il)isoindolin-2-il)piperidina-2,6-diona e usos dos mesmos
BR112021015672A2 (pt) 2019-02-15 2021-10-05 Novartis Ag Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona substituída e usos dos mesmos
WO2021116789A1 (fr) 2019-12-09 2021-06-17 Novartis Ag Anticorps anti-interleukine 1 bêta pour le traitement de la drépanocytose
EP4309722A2 (fr) 2019-12-13 2024-01-24 Biora Therapeutics, Inc. Dispositif ingérable pour l'administration d'un agent thérapeutique au tractus gastro-intestinal
KR20220116257A (ko) 2019-12-20 2022-08-22 노파르티스 아게 골수섬유증 및 골수이형성 증후군을 치료하기 위한, 데시타빈 또는 항 pd-1 항체 스파르탈리주맙을 포함하거나 또는 포함하지 않는, 항 tim-3 항체 mbg453 및 항 tgf-베타 항체 nis793의 조합물
TWI793503B (zh) 2020-01-20 2023-02-21 美商美國禮來大藥廠 抗IL-1β抗體
US20230220065A1 (en) * 2020-06-16 2023-07-13 Academia Sinica Antibodies to interleukin-1beta and uses thereof
CN115916199A (zh) 2020-06-23 2023-04-04 诺华股份有限公司 包含3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物的给药方案
WO2022023907A1 (fr) 2020-07-31 2022-02-03 Novartis Ag Méthodes de sélection et de traitement de patients présentant un risque élevé d'événements cardiaques indésirables majeurs
IL302569A (en) 2020-11-06 2023-07-01 Novartis Ag CD19 binding molecules and their uses
WO2022167916A1 (fr) 2021-02-03 2022-08-11 Novartis Ag Utilisation d'anticorps se liant à l'il-1b pour le traitement de troubles neuro-inflammatoires
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
AR125874A1 (es) 2021-05-18 2023-08-23 Novartis Ag Terapias de combinación
WO2022249040A1 (fr) 2021-05-24 2022-12-01 Novartis Ag Méthodes de traitement de l'arthrose
CA3219360A1 (fr) 2021-06-22 2022-12-29 Novartis Ag Anticorps bispecifiques destines a etre utilises dans le traitement de l'hidrosadenite suppuree

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US534858A (en) * 1895-02-26 Workman s time-recorder
CA1172789A (fr) 1980-09-25 1984-08-14 Hideo Kasahara POLYMERE RENFERMANT UN POLYAMIDE LIE A UN COPOLYMERE QUI CONTIENT UN IMIDE D'ACIDE CARBOXYLIQUE INSATURE EN .alpha.,.beta.
US4772685A (en) 1985-10-02 1988-09-20 Merck & Co., Inc. Immunogenic peptides of human interleukin-1 and the corresponding anti-peptide antibodies
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4935343A (en) 1986-08-08 1990-06-19 Syntex (U.S.A.) Inc. Monoclonal antibodies for interleukin-1β
EP0281604B1 (fr) 1986-09-02 1993-03-31 Enzon Labs Inc. Molecules de liaison de chaines de polypeptide simples
DK590387A (da) 1986-11-13 1988-05-14 Otsuka Pharma Co Ltd Antistoffer mod interleukin-1
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
DE68925935T2 (de) 1988-10-01 1996-08-14 Otsuka Pharma Co Ltd Antikörper gegen Interleukin-1-beta
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
FR2640146B1 (fr) 1988-12-08 1993-12-24 Commissariat A Energie Atomique Anticorps monoclonaux anti-interleukines 1(alpha) et 1(beta), leur procede de production et applications desdits anticorps a la detection des interleukines 1(alpha) et 1(beta) et en therapeutique
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
CA2018248A1 (fr) 1989-06-07 1990-12-07 Clyde W. Shearman Anticorps monoclonaux contre le recepteur alpha-beta de cellules t humaines, leur production et leur utilisation
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
SG48759A1 (en) 1990-01-12 2002-07-23 Abgenix Inc Generation of xenogenic antibodies
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
EP0546073B1 (fr) 1990-08-29 1997-09-10 GenPharm International, Inc. production et utilisation des animaux non humains transgeniques capable de produire des anticorps heterologues
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
JP3714683B2 (ja) 1992-07-30 2005-11-09 生化学工業株式会社 抗リウマチ剤
US5429614A (en) 1993-06-30 1995-07-04 Baxter International Inc. Drug delivery system
WO1995001997A1 (fr) * 1993-07-09 1995-01-19 Smithkline Beecham Corporation ANTICORPS RECOMBINANTS ET HUMANISES, DIRIGES CONTRE L'IL-1β ET DESTINES AU TRAITEMENT DE TROUBLES INFLAMMATOIRES INDUITS PAR IL-1 CHEZ L'HOMME
US6309636B1 (en) * 1995-09-14 2001-10-30 Cancer Research Institute Of Contra Costa Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides
US6051228A (en) 1998-02-19 2000-04-18 Bristol-Myers Squibb Co. Antibodies against human CD40
GB0001448D0 (en) 2000-01-21 2000-03-08 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
JP2008295456A (ja) 2008-12-11
WO2002016436A3 (fr) 2002-06-20
ZA200301275B (en) 2004-04-02
IL154465A (en) 2010-11-30
KR20080056316A (ko) 2008-06-20
AR035581A1 (es) 2004-06-16
NO2017052I2 (no) 2018-05-14
US7446175B2 (en) 2008-11-04
CY1108779T1 (el) 2012-01-25
NZ534269A (en) 2006-04-28
PE20020319A1 (es) 2002-06-11
SI1313769T2 (sl) 2012-01-31
EP1313769A2 (fr) 2003-05-28
EP1313769B1 (fr) 2008-05-21
BRPI0113420B8 (fr) 2021-05-25
CN100547003C (zh) 2009-10-07
CN1484652A (zh) 2004-03-24
MY130248A (en) 2007-06-29
NL300427I2 (en) 2010-02-01
HUS1300015I1 (hu) 2021-05-28
MXPA03001590A (es) 2003-06-04
AU2001295490B2 (en) 2005-06-16
LU91624I9 (fr) 2018-11-19
TWI321568B (en) 2010-03-11
NL300427I1 (en) 2010-02-01
DK1313769T4 (da) 2011-12-05
AU9549001A (en) 2002-03-04
US20110256151A1 (en) 2011-10-20
CY2009019I2 (el) 2017-07-12
HK1061403A1 (en) 2004-09-17
EP1313769B2 (fr) 2011-11-09
DK1313769T3 (da) 2008-09-15
US7993878B2 (en) 2011-08-09
NZ524199A (en) 2004-09-24
IL154465A0 (en) 2003-09-17
ECSP034490A (es) 2003-03-31
ATE396206T1 (de) 2008-06-15
US8273350B2 (en) 2012-09-25
BRPI0113420B1 (pt) 2002-02-28
FR09C0062I2 (fr) 2010-12-31
ES2305110T5 (es) 2012-03-13
NO20030827D0 (no) 2003-02-21
JP2004506448A (ja) 2004-03-04
CZ2003505A3 (cs) 2003-05-14
DE60134148D1 (de) 2008-07-03
PL360358A1 (en) 2004-09-06
HUP0300806A2 (hu) 2003-12-29
PT1313769E (pt) 2008-08-26
JP4271936B2 (ja) 2009-06-03
NO2017052I1 (no) 2017-10-11
HU228159B1 (en) 2013-01-28
NO2012018I1 (no) 2012-12-10
NO20030827L (no) 2003-04-14
SI1313769T1 (sl) 2008-10-31
GB0020685D0 (en) 2000-10-11
CA2420231C (fr) 2011-04-26
FR09C0062I1 (fr) 2010-08-01
CY2009019I1 (el) 2012-01-25
SK2132003A3 (en) 2003-10-07
HUP0300806A3 (en) 2005-09-28
PL212480B1 (pl) 2012-10-31
DE122009000078I1 (de) 2010-03-25
WO2002016436A2 (fr) 2002-02-28
CZ304470B6 (cs) 2014-05-21
SK288089B6 (sk) 2013-06-03
ES2305110T3 (es) 2008-11-01
BE2009C057I2 (fr) 2021-01-28
NO2012018I2 (no) 2012-11-21
US20090081732A1 (en) 2009-03-26
NO332609B1 (no) 2012-11-19
KR20030034140A (ko) 2003-05-01
US20040063913A1 (en) 2004-04-01
KR100910789B1 (ko) 2009-08-04
RU2286351C2 (ru) 2006-10-27
BR0113420A (pt) 2003-07-29
CA2420231A1 (fr) 2002-02-28

Similar Documents

Publication Publication Date Title
LU91624I2 (fr) Canakinumab et ses dérivés pharmaceutiquement acceptables (ILARIS®)
LU92381I2 (fr) Macitentan et ses dérivés pharmaceutiquement acceptables (OPSUMIT)
LU92024I2 (fr) Pasireotide et ses dérivés pharmaceutiquement acceptables (SIGNIFOR)
LU92513I2 (fr) Sofosbuvir et ses dérivés pharmaceutiquement acceptables (solvaldi)
LU91757I2 (fr) Denosumab et ses dérivés pharmaceutiquement acceptables (PROLIA®)
LU92419I2 (fr) Riociguat et ses dérivés pharmaceutiquement acceptables (ADEMPAS®)
LU92517I2 (fr) Delamanide et ses dérivés pharmaceutiquement acceptables
LU92336I2 (fr) Trastuzumab emtansine et ses dérivés pharmaceutiquement acceptables (KADCYLA)
LU92745I2 (fr) Nétupitant/Palonosétron et leurs dérivés pharmaceutiquement acceptables (AKYNZEOr)
LU92871I2 (fr) Fumarate de diméthyle et ses dérivés pharmaceutiquement acceptables (tecfidera)
LU91269I2 (fr) Rotigotine et ses dérivés pharmaceutiquement acceptables (neupro)
CY2013011I2 (el) Μεθοδος χορηγησης διφωσφονικων
LU91883I2 (fr) Pradofloxacin et ses dérivés pharmaceutiquement acceptables (VERAFLOX®)
LU91346I2 (fr) Lumiracoxib et ses dérivés pharmaceutiquement acceptables (prexige)
LU91251I2 (fr) Vaccin à rotavirus (vivant) et ses dérivés pharmaceutiquement acceptables (ROTARIXr)
LU91122I2 (fr) Efalizumab et ses dérivés pharmaceutiquement acceptables (raptiva).
LU92326I2 (fr) Canakinumab et ses dérivés pharmaceutiquement acceptables (ILARIS)
IS6254A (is) Lyfjasamsetningar sem innihalda HMG afoxunarensímlata
LU91138I2 (fr) Glulisine d'insuline et ses dérivés pharmaceutiquement acceptables.
LU91501I2 (fr) Sugammadex et ses sels pharmaceutiquement acceptables-BRIDION
LU91189I2 (fr) Atazanavir sulphate et ses dérivés pharmaceutiquement acceptables (REYATAZ)
DE60142197D1 (de) Pharmazeutische Zusammensetzung
LU91076I2 (fr) Tulathromycin et ses sels pharmaceutiquement acceptables (draxxin).
LU92634I2 (fr) Flutémétamol (18f) et ses dérivés pharmaceutiquement acceptables (vizamyl)
EE200200555A (et) Farmatseutiliselt aktiivsed pürrolidiini derivaadid